DoorDash Inc vs DexCom, Inc. — how do they compare? DoorDash Inc trades at $196.19 (market cap $83.07B), while DexCom, Inc. trades at $84.03 (market cap $31.86B). The key difference: DoorDash Inc is far larger — about 2.6× DexCom, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, DoorDash Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and DexCom, Inc. for 62 Days on average.
| DASH | DXCM | |
|---|---|---|
Market Cap | $83.07B | $31.86B |
Volume | 3,242,567 | 3,607,070 |
Sector | Media | Health |
52-Week High | $275.44 | $92.34 |
52-Week Low | $146.60 | $54.84 |
Typical Hold Time | 59 Days | 62 Days |
Enterprise Value | $81.03B | $31.32B |
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $196.33, up 2.66% today, with a bullish technical signal from moving averages. The company shows strong revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent developments include AI-powered text ordering and drone delivery expansion. Analyst consensus remains strongly bullish with 75% buy ratings and a $255.80 price target, representing 30% upside potential from current levels.
The outlook remains positive with continued revenue growth projected to $15.9B in 2026, though net income may moderate to $841M. Key risks include competitive pressures, regulatory scrutiny from ongoing investigations, and execution challenges in new initiatives. The stock trades at premium valuations (P/E 100.37) requiring sustained growth to justify current levels.
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →